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ABSTRACT 
Multiple sclerosis (MS) is a prevalent neurological disease of complex etiology. Here we 
describe the characterization of a multi-incident MS family which nominated a rare missense 
variant (p.G420D) in plasminogen (PLG) as a putative genetic risk factor for MS. Genotyping of 
PLG p.G420D (rs139071351) in 2160 MS patients and 886 controls from Canada identified ten 
additional probands, two sporadic patients and one control with the variant. Segregation analysis 
in families harboring the rs139071351 variant, identified p.G420D in 26 out of 30 family 
members diagnosed with MS, 14 unaffected parents and 12 out of 30 family members not 
diagnosed with disease. Despite considerably reduced penetrance, linkage analysis supports co-
segregation of PLG p.G420D and disease. Genotyping of PLG p.G420D in 14446 patients and 
8797 controls from Canada, France, Spain, Germany, Belgium and Austria failed to identify 
significant association with disease (p=0.117), despite an overall higher prevalence in patients 
(OR=1.32; 95% CI=0.93-1.87). To assess whether additional rare variants have an effect on MS 
risk, we sequenced PLG in 293 probands and genotyped all rare variants in cases and controls. 
This analysis identified nine rare missense variants, and although three of them were exclusively 
observed in MS patients segregation analyses do not support pathogenicity. PLG is a plausible 
biological candidate for MS owing to its involvement in immune system response, blood-brain 
barrier permeability and myelin degradation. Moreover, components of its activation cascade 
have been shown to present increased activity or expression in MS patients compared to controls; 
further studies are needed to clarify whether PLG is involved in MS susceptibility. 
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INTRODUCTION 
Multiple sclerosis (MS) is a chronic inflammatory demyelinating and neurodegenerative disease 
of the central nervous system. The genetic contribution to disease susceptibility has been 
demonstrated in family and twin studies (Ebers et al. 1986; Sadovnick 1993; Fagnani et al. 
2015), and the first pathogenic mutation for MS has been recently identified in NR1H3 (Wang et 
al. 2016). In addition, a large number genetic risk factors, primarily related to the immune 
system, have already been identified through association studies (Beecham et al. 2013; Sawcer et 
al. 2011). However, with the exception of HLA-DRB1, all associated variants have a minor effect 
on overall disease. The identification of genetic components of major effect on disease 
development is paramount for the generation of physiologically relevant cellular and animal 
models of human disease, and the generation of treatment strategies that address the underlying 
biological mechanisms responsible for the onset of MS. 
MATERIAL AND METHODS 
Participants 
A total of 2160 MS patients and 886 unrelated healthy controls from Canada, which includes 
1857 multi-incident families, collected through the Canadian Collaborative Project on the 
Genetic Susceptibility to Multiple Sclerosis (CCPGSMS) were included in this study.(Sadovnick 
et al. 1998). Five independent European cohorts consisting of 2391 MS patients and 672 healthy 
controls from France, 4288 patients and 4018 controls from Spain, 3733 patients and 2722 
controls from Germany, 1006 patients and 504 controls from Belgium and 925 patients from 
Austria were used for replication. All patients were diagnosed with MS according to published 
criteria (Poser et al. 1983; McDonald et al. 2001; Polman et al. 2005), and the demographics for 
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each cohort are presented in Table 1. The ethical review board at each institution approved the 
study, and all participants provided written informed consent. 
Exome sequencing 
We performed exome sequencing in three patients diagnosed with MS (pedigree A; II-1, II-4 and 
III-1) from a multi-incident family (Figure 1). Exonic regions were enriched using an Ion 
AmpliSeq exome kit (57.7Mb) and sequenced in an Ion Proton sequencer (Life Technologies, 
Carlsbad, CA, USA) with a minimum average coverage of 50 reads per base and an average read 
length of 150 bases. The Ion Torrent Server v4 was used to map reads to NCBI Build 37.1 
reference genome using the Torrent Mapping Alignment Program (TMAP) and to identify 
variants differing from the reference. Sequences with a mapping Phred quality score under 20, 
fewer than five reads or over 95% strand bias were excluded from further analysis. 
Sequencing, genotyping and statistical analysis 
Sanger sequencing was used to genotype amplicons containing exome variants of interest and all 
19 coding exons and exon-intron boundaries of plasminogen (PLG, NM_000301.3) by 
polymerase chain reaction (PCR) as previously described (Sadovnick et al. 2013). Nine tagging 
SNPs (tSNPs) spanning a 61 kb region encompassing the PLG locus were selected based on 
HapMap data (version 3 release 27) using Haploview software (Barrett et al. 2005). Selected 
tSNPs captured over 92% of the polymorphic variation in the region (minor allele frequency 
(MAF)>5% and r2>0.8) in Caucasian population standards. Genotyping of variants was 
performed using a combination of TaqMan probes and Sequenom MassArray iPLEX as 
previously described (Traboulsee et al. 2014; Nishioka et al. 2010). Genotyping success rate was 
over 99.4% for all variants and without deviation from Hardy-Weinberg equilibrium expectation 
(p-value > 0.005). Statistical association was determined using logistic regression analysis 
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adjusted for age and gender, in addition the combined cohort analysis was adjusted for site. 
Genotypes were dichotomized as presence versus absence of the minor allele (dominant model). 
The combined dataset was obtained by pooling samples from all populations. Segregation 
analysis was quantified using non-parametric and parametric linkage analysis. Non-parametric 
linkage analysis were performed using SimWalk2 software (version 2.91) and NPL-All statistic 
(Sobel et al. 2001). Two-point parametric logarithm of odds (LOD) score were obtained with 
MLINK assuming a dominant model, with a fully penetrant disease and without phenocopies 
(Ott 1989). All MS patients were treated as affected, non-carrier individuals as healthy and 
unaffected mutation carriers were treated as having an unknown disease status. The deleterious 
allele was defined with a 0.0001 frequency and the marker-allele frequency determined 
empirically from genotyped individuals. 
Haplotype analysis 
Microsatellite markers spanning the PLG locus between D6S1633 and D6S297 were chosen to 
define the disease-carrying haplotype (Supplementary Table 1). All family members from those 
families identified with the PLG p.G420D mutation were genotyped. One primer for each pair 
was labeled with a fluorescent tag and PCR reactions were performed under standard conditions. 
PCR products were run on an ABI 3730xl (Life Technologies, Carlsbad, CA, USA), and 
analyzed using GeneMapper 4.0. Marker sizes were normalized to those reported in the CEPH 
database and manually phased within each family. 
RESULTS 
To identify genes and variants of major effect on MS susceptibility, we applied exome 
sequencing analysis to a multi-incident family consisting of 12 individuals over three 
generations, with DNA available for nine family members, including six diagnosed with MS 
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(Figure 1A). Exome analysis of II-1, II-4 and III-1 identified 47479, 46545 and 46580 variants, 
respectively. Of those, 25 missense variants with a MAF below 1% from public and proprietary 
databases of variants were identified in all three individuals (Supplementary Table 2). 
Segregation analysis in additional family members identified ten variants shared amongst at least 
five of the six family members diagnosed with MS for whom DNA was available, and no more 
than one of the two unaffected blood relatives. Three of these variants were subsequently 
excluded as they were identified at a frequency over 1% in 366 ethnically matched controls 
(Supplementary Table 2). The seven remaining variants were genotyped in a multi-ethnic cohort 
consisting of 2160 MS patients and 886 unrelated healthy controls from Canada. Three variants 
(TGFBI, p.V608L (ss1467426521); SPINK13, p.C72R (ss1467426567); OR1E1, p.D96Y 
(ss1467426912)) appear to be private as they were not observed in any of the other samples 
genotyped in this study and have not been described in public databases of variants (Abecasis et 
al. 2012; Exome Aggregation Consortium et al. 2015). ARHGAP10, p.T518K (rs375188932), 
with a reported MAF of 5x10-5 in the ExAC database, was also not observed in any additional 
samples. Segregation of these four variants within the exome sequenced family is provided in 
supplementary figure 1. Of the remainder, SPATA18 p.P286L (rs150116592) was identified in 
two MS patients, UNC45B p.R776Q (rs34242925) was identified in one patient and one control, 
and PLG p.G420D (rs139071351) in 12 MS patients and one control. 
Segregation analysis for variants identified in SPATA18 and UNC45B did not support co-
segregation with disease in additional families and were excluded from further analysis 
(Supplementary Figure 1). Segregation analysis of PLG p.G420D identified the variant in 26 out 
of 30 family members diagnosed with MS (87%), 14 parents of MS patients (including eight 
obligate carriers) not known to suffer from MS, and 12 out of 30 family members not diagnosed 
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with disease (Figure 1B-M). To quantifiably assess segregation we performed nonparametric and 
parametric linkage analysis for PLG p.G420D. The more conservative nonparametric score 
resulted in a LOD score of 1.29, whereas parametric linkage analysis resulted in a maximum 
LOD score of 5.48 (theta=0.05), despite a penetrance estimate of 50%. Additional support for a 
role in disease susceptibility is provided by the level of conservation for the glycine residue in 
mammals, indicating the importance of this amino acid for protein function (Figure 2). 
Haplotype analysis of PLG p.G420D carriers between D6S1633 and D6S297 did not identify a 
shared haplotype amongst families (Supplementary Table 1), thus suggesting that PLG p.G420D 
is a mutational hotspot that has independently arisen in each family rather than being inherited 
from a common ancestor. 
Clinical details were available for 17 PLG p.G420D carriers, five males and 12 females 
(Supplementary Table 3). The disease course observed in these carriers was predominantly 
consistent with relapsing-remitting MS or secondary progressive MS with only two patients 
presenting primary progressive MS. On average, the age at onset of disease was 35.1 years (SD ± 
9.1) with a disease duration of 19.9 years (SD ± 10.4). Disease severity was overall relatively 
moderate, with an average expanded disability status scale (EDSS) score of 3.92 (SD ± 2.9) and 
a median of 2.75. 
Association analysis of PLG p.G420D was performed in Caucasian samples from Canada 
already genotyped for the identification of additional PLG p.G420D families. This subset 
consists of 2103 MS patients and 881 controls, and resulted in a marginally significant 
association with disease risk (p=0.046) and an odds ratio (OR) of 10.19 (Table 1). In order to 
validate this association we genotyped PLG p.G420D in five independent cohorts from Europe 
consisting of 12343 MS patients and 7916 healthy controls. Logistic regression analysis 
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corrected for age and gender identified a similarly marginal association with disease in the 
French cohort (p=0.049; OR=2.69) whereas no association was observed for any additional 
cohort (Table 1). Although the combined dataset did not result in a significant association with 
disease risk (p=0.117), with the exception of Belgium which is the smallest set, all cohorts 
resulted in OR greater than 1, indicating a higher prevalence of PLG p.G420D in MS patients 
than controls. 
To assess whether common variants in PLG lead to an increased susceptibility to develop MS, 
we identified nine tSNPs spanning the entire PLG loci and genotyped them in 2103 MS patients 
and 881 controls from Canada (Supplementary Table 4). Association analysis failed to identify a 
significant association between any of the tSNPs and susceptibility to MS (p>0.05). Since 
common variants in PLG do not appear to have an effect on MS disease risk, we assessed for the 
presence of additional rare PLG substitutions in MS patients. To this end we sequenced all PLG-
coding exons in 293 familial probands from Canada, which identified 11 silent and 11 missense 
variants (Supplementary Table 5). Of those, nine missense variants with a MAF below 1% in at 
least two of three publicly available databases (1000G, ExAC or ESP) were genotyped in cases 
and controls from Canada (Abecasis et al. 2012; Exome Aggregation Consortium et al. 2015; 
Exome Sequencing Project). This analysis identified six variants (p.K38E, p.R89K, p.R261H, 
p.R490Q, p.A494V and p.R523W) at similar frequencies in MS patients and controls; whereas 
p.T200A (rs149145958), p.T500M (rs140970354) and p.A507V (rs372603134) were only 
identified in eight, two and one MS patient, respectively (Table 2). Despite all three variants 
being predicted likely damaging to protein function with a phred-scaled CADD score of 29.3, 
14.4 and 18.9 for p.T200A, p.T500M and p.A507V, respectively (Kircher et al. 2014); and two 
of them being evolutionarily conserved (Figure 2), segregation and parametric linkage analysis, 
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which resulted in negative LOD scores, does not support a role for these variants in disease 
pathogenicity (Supplementary Figure 2). 
DISCUSSION 
Exome sequencing analysis in a multi-incident family suffering from MS has nominated PLG 
p.G420D as a putative new risk factor for MS. Although four private missense variants cannot be 
conclusively excluded as a potential cause of disease in this kindred, and copy number changes 
were not evaluated, the identification of PLG p.G420D in twelve additional MS patients and one 
control from Canada suggests a role for PLG in MS susceptibility. Genotyping of additional 
family members from multi-incident families with PLG p.G420D resulted in positive co-
segregation of the variant and disease, albeit with 50% reduced penetrance (Figure 1). Additional 
support for pathogenicity was sought from a large case-control cohort of MS patients from 
Europe; and although most populations present a higher prevalence of PLG p.G420D in MS 
patients than controls, a nominally significant difference was only observed in the French cohort 
(Table 1). A possible Acadian origin of PLG p.G420D was considered due to the marginal 
associations in the French and Canadian population; however, the wide geographical distribution 
of variant carriers from Canada and the lack of a shared ancestral haplotype (Supplementary 
Table 1) do not support this hypothesis. Association analysis for PLG p.G420D in the entire 
cohort resulted in a non-significant p-value of 0.117 and an OR of 1.32. Despite the overall lack 
of association observed, it is possible that carriers of the PLG p.G420D variant have an increased 
risk of developing MS, as suggested by the OR and initially observed familial segregation 
pattern. In contrast, common PLG tagging variants genotyped in this study were clearly not 
associated with MS risk in the Canadian population (Supplementary Table 4). This data 
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corroborates previously described genome wide association studies which did not nominate 
common variants in PLG as a risk factor for MS (Beecham et al. 2013; Sawcer et al. 2011). 
Sequencing of PLG in MS patients from Canada led to the identification of nine rare missense 
variants (Table 2). Six of which were subsequently identified at a similar frequency in MS 
patients and controls, suggesting they are not likely to have an effect on MS risk. Interestingly 
one of these variants (p.K38E, rs73015965) has been described as the cause of PLG deficiency 
type I when identified in homozygous or compound heterozygous form (Tefs et al. 2006). 
Similarly, p.R523W (rs4252129) has been associated with decreased plasma PLG levels (Ma et 
al. 2014). Severe PLG deficiency type I has been causally linked to ligneous conjunctivitis, a rare 
chronic inflammatory disease of mainly mucous membranes. Although there is no indication that 
heterozygous carriers are at an increased risk of developing disease (Tefs et al. 2006), PLG 
dysregulation could lead to an increased susceptibility to inflammatory and autoimmune 
diseases. In our study, three additional variants (p.T200A, p.T500M and p.A507V) not known to 
cause hypoplasminogenemia, were observed exclusively in MS patients. Although the allelic 
frequencies and segregation analysis for rare missense PLG variants do not initially support a 
role in disease susceptibility, genotyping in additional MS patients is warranted to fully define 
these preliminary findings. PLG p.T200A seems of particular interest, as it was identified in 
eight MS patients and no controls (Table 2), it is evolutionary conserved (Figure 2), and a 
threonine to proline substitution at the same position has been identified in a patient with severe 
type I PLG deficiency (Tefs et al. 2006). 
PLG is a plausible biological candidate for MS susceptibility as it is involved in the 
inflammatory response, blood-brain barrier (BBB) permeability, neuronal viability, and myelin 
degradation (Syrovets et al. 2012; Yao and Tsirka 2011; Chen and Strickland 1997; Cuzner and 
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Opdenakker 1999). PLG has been shown to play a role in the immune response, with plasmin 
deficiency, the active form of PLG, resulting in a compromised inflammatory response in mouse 
brain (Hultman et al. 2014). Microglia and astrocytes are the primary mediators of inflammation 
in the central nervous system, and fibrin has been shown to activate their immune response by 
stimulating the production of inflammatory mediators including proinflammatory cytokines and 
reactive oxygen species, as well as act as a chemoattractant for immune cells (Syrovets et al. 
2012; Hultman et al. 2014). 
Genetic variants in PLG may also have an effect on brain inflammation by altering the BBB 
permeability. Plasmin alters BBB permeability by inducing morphological changes in brain 
astrocytes and endothelial cells through the reorganization of the actin cytoskeleton and the 
redistribution of tight junction proteins (Niego and Medcalf 2014; Yao and Tsirka 2011). In 
addition to its effects on the inflammatory response and BBB permeability, plasmin has also 
been shown to affect neuronal viability, including sprouting, plasticity and extracellular matrix-
related neuronal death (Chen and Strickland 1997; Nakagami et al. 2000; Wu et al. 2000). 
Plasmin activates highly active matrix metalloproteinases (MMPs) which are recognized as key 
proteases in the demyelination process. Synthetic inhibitors of MMPs have been found to 
ameliorate clinical symptoms and pathological signs in experimental autoimmune 
encephalomyelitis (EAE) animal models (Cuzner and Opdenakker 1999); and minocycline, 
which has several immunomodulating activities including the inhibition of MMP-9, has being 
successfully used in clinical trials as an add-on therapy for MS patients (Metz et al. 2009).  
Despite the existence of extended families with a high incidence of MS (Fagnani et al. 2015; 
Sadovnick 1993), only one rare pathogenic mutations has been reported (Wang et al. 2016). In 
this study, the implementation of exome sequencing analysis in a multi-incident MS family 
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nominated PLG p.G420D as a potential susceptibility risk for MS. Additional support was 
provided by 10 additional multi-incident MS families in which the variant segregates with 
disease, albeit with reduced penetrance. Disappointingly, genotyping of PLG p.G420D in a large 
European case-control cohort failed to identify a significant association with MS, thus not 
supporting a role in disease. Despite this lack of association, dysregulation of the PLG/plasmin 
activation cascade is a plausible pathomechanism of MS; which in conjunction with the positive 
segregation of PLG p.G420D in families (Figure 1), the overall higher incidence of PLG 
p.G420D carriers in European MS patients (Table 1), and the identification of additional rare 
PLG substitutions in MS patients not observed in controls (Table 2), warrants further genetic and 
functional characterization of PLG in order to elucidate its potential role on MS susceptibility 
and pathogenesis. 
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FIGURE LEGENDS 
Figure 1. Simplified pedigrees for families presenting the PLG p.G420D variant. Males are 
represented by squares and females by circles, the proband is indicated with an arrow head. 
Patients diagnosed with MS have black filled symbols and carriers of unknown clinical 
phenotype have grey filled symbols. Heterozygote carriers (M) and wild-type (wt) genotypes are 
indicated. An asterisk indicates an inferred carrier. Pedigree A was used for exome analysis, and 
with the exception of pedigree E, which is of Asian descent, all families are of Caucasian 
ancestry. 
Figure 2. PLG variants and cross-species conservation. Protein orthologs were aligned via 
ClustalO. Amino acid positions for PLG variants are highlighted in black. Protein orthologs with 
amino acid positions differing from those of the human sequence are indicated in gray. RefSeq 
accession numbers: Homo sapiens NP_000292.1, Macaca mulatta NP_001036540.1, Mus 
musculus NP_032903.3, Rattus norvegicus NP_445943.1, Canis lupus familiaris 
NP_001273889.1, Sus scrofa NP_001038055.1, Bos taurus NP_776376.1, Myotis davidii 
ELK34830.1, Tarsius syrichta XP_008066085.1, Gallus gallus XP_419618.2, Danio rerio 
AAH59801.1. 
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Table 1. Logistic regression analysis for PLG p.G420D (rs139071351) and risk of MS. F, female; M, male; OR, odds ratio; CI, 
confidence interval; NA, not applicable. 
 Group Gender 
F:M 
Age 
(mean ± SD) 
Age at onset 
(mean ± SD) 
Genotypes 
(GA/GG) 
p-value OR (95% CI) 
Canada Controls 1:1.04 67.1 ± 9.8  1/880 0.046 10.19 (1.04-267.89) 
MS patients 1:0.37 46.7 ± 11.7 31.0 ± 9.7 12/2091   
France Controls 1:0.64 39.3 ± 13.1  4/668 0.049 2.69 (1.00-9.37) 
MS patients 1:0.43 49.1 ± 11.4 30.5 ± 9.7 32/2359   
Spain Controls 1:0.68 42.8 ± 12.8  34/3984 0.475 1.20 (0.73-1.96) 
MS patients 1:0.53 44.5 ± 11.5 30.9 ± 9.8 42/4246   
Germany Controls 1:0.68 41.3 ± 16.8  11/2711 0.476 1.31 (0.63-2.84) 
MS patients 1:0.41 40.5 ± 11.3 30.8 ± 10.3 21/3712   
Belgium Controls 1:0.89 56.2 ± 14.7  5/499 0.747 0.81 (0.23-3.04) 
MS patients 1:0.52 48.3 ± 13.1 33.3 ± 10.9 6/1000   
Austria MS patients 1:0.43 49.2 ± 12.1 28.7 ± 9.1 7/918 NA NA 
Combined Controls 1:0.72 44.3 ± 15.9  55/8742 0.117 1.32 (0.93-1.87) 
MS patients 1:0.45 45.1 ± 12.1 30.9 ± 9.9 120/14326   
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Table 2. Case-control frequency for rare missense PLG variants identified in MS patients. 
dbSNP IDa 
Chromosome 
and position 
Nucleotide 
change 
Protein 
change 
Minor allele frequency 
ExACb Controls (n) MS (n) 
rs73015965 6:161127501 A/G p.K38E 0.003 0.006 (10) 0.007 (28) 
rs143079629 6:161128812 G/A p.R89K 0.007 0.010 (16) 0.010 (44) 
rs149145958 6:161135876 A/G p.T200A 0.001 0 0.002 (8) 
rs4252187 6:161137790 G/A p.R261H 0.003 0.007 (12) 0.005 (24) 
rs140537724 6:161152807 G/A p.R490Q 0.001 0.002 (3) 0.002 (9) 
rs4252128 6:161152819 C/A p.A494V 0.008 0.005 (8) 0.005 (20) 
rs140970354 6:161152837 C/T p.T500M 0.0002 0 0.0005 (2) 
rs372603134 6:161152858 C/T p.A507V 0.0001 0 0.0002 (1) 
rs4252129 6:161152905 C/T p.R523W 0.007 0.012 (19) 0.013 (56) 
adbSNP Build 138, bThe Exome Aggregation Consortium (ExAC) database 
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Figure 1 
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Figure 2. 
 
                 T200A                   G420D                   T500M  A507V 
Human     ENYDGKISKTMSGLECQAW     KTPENYPNAGLTMNYCRNP     GKRATTVTGTPCQDWAAQEPHRHSIF 
Monkey    ENYDGKISKTMSGLECQAW     KTPENFPNAGLTMNYCRNP     GKKATTVTGTPCQEWAAQEPHSHRIF 
Mouse     EKYEGKISKTMSGLDCQAW     KTPENFPDAGLEMNYCRNP     GKTAVTAAGTPCQGWAAQEPHRHSIF 
Rat       EKYEGKISKTMSGLDCQSW     KTPANFPDAGLEMNYCRNP     GKTAVTAAGTPCQEWAAQEPHSHRIF 
Dog       ENYEGKISKTKSGLECQAW     KTPEHFPEAGLTMNYCRNP     GKKATTVMGIPCQEWAAQEPHRHSIF 
Pig       EHYEGKISKTMSGIECQSW     KTPGNFPNAGLTMNYCRNP     GKRATTVAGVPCQEWAAQEPHRHSIF 
Bull      ENYEGKIAKTMSGRDCQAW     KTPENYPNAGLTMNYCRNP     GKKATTVAGVPCQEWAAQEPHQHSIF 
Bat       ENYEGTISRTKSGLECQAW     MTPGKVPNAGLTMNYCRNP     GKRATTVAGTTCQAWAAQEPHRHSIF 
Tarsier   ENYEGKISKTMSGLECQAW     KTAENYPNAGLEMNYCRNP     GKRATTVTGTPCQEWAAQEPHRHSIF 
Chicken   ENYHGVVATTASGLECQRW     KTSEHFPNADLRQNYCRNP     GTVARTARGRICQEWSSQTPHKHDYF 
Fish      ENYRGKISTTVSGFTCQRW     KTPQNFPKADLRRNLCRNP     GSTSMTVMGVTCQAWRSMTPHQHASF 
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Supplementary Figure 1. Segregation analysis of exome variants. Males are represented by 
squares and females by circles, with the proband indicated with an arrow head. Patients 
diagnosed with MS have black filled symbols. Heterozygote carriers (M) and wild-type (WT) 
genotypes are indicated. 
 
ARHGAP10 p.T518K (rs375188932) TGFBI p.V608L (ss1467426521) 
 Original family (Fig1 A) Original family (Fig1 A) 
 
 
SPINK13 p.C72R (ss1467426567) OR1E1 p.D96Y (ss1467426912) 
 Original family (Fig1 A) Original family (Fig1 A) 
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SPATA18 p.P286L (rs150116592) 
 Original family (Fig1 A) 
 
 
 
 
 Additional families 
 
 
 
 
 
UNC45B p.R776Q (rs34242925) 
 Original family (Fig1 A) Additional family 
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Supplementary Figure 2. Segregation analysis of PLG variants not observed in controls. 
Males are represented by squares and females by circles, with the proband indicated with an 
arrow head. Patients diagnosed with MS have black filled symbols. Heterozygote carriers (M) 
and wild-type (wt) genotypes are indicated. Inferred carriers are indicated with an asterisk. 
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PLG p.T500M (rs140970354) PLG p.A507V (rs372603134) 
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Supplementary Table 1. Chromosome 6q25.3-27 haplotypes carrying PLG p.G420D. Microsatellite allele sizes are given in base 
pairs consistent with Centre d’Etude du Polymorphisme Humain (CEPH) standards. For markers with an unknown phase both alleles 
are given. Markers are shown with their physical locations according to NCBI Build 37.1. 
 
Marker Position 
Family ID 
A B C D E F G H J I K L M 
D6S1633 157,016,443 129 125 121 129 119 131 117 121 117 121 121/129 127 121/129 
D6S415 157,794,580 263 275 275 265 263 261 261 265 261 265 267 261 263/275 
D6S1655 158,300,596 149 149 149/163 165 151 155 149 155 153 155 149 155 149 
D6S437 158,683,884 135 153 131 131 161 163 131 147 131 135 131/153 131 131/159 
D6S1581 160,196,757 219 229 219 219 219 219 219 219 227 219 219/227 219 215 
rs139071351 161,152,085 A A A A A A A A A A A A A 
D6S305 162,115,166 218 204 226 224 218 204 218 218 232 204 226 204 226 
D6S1599 162,759,584 151 147 131 131 131 133 133 133 143 133 133 133 155 
D6S1277 164,217,713 290 296 294/296 296 296 298 302 298 298 298 298 298 298 
D6S1719 165,989,655 180 184 182 178 178 180 174 174 182 178 178 178 182 
D6S297 167,156,674 222 212 222 214 212 222 212 212 212 222 222 212 212 
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Supplementary Table 2. Novel and rare (MAF<0.01) missense variants shared by family A 
members II-1, II-4 and III-1. Chromosomal positions are provided in reference to NCBI Build 
37.1. 
Chr Position Gene 
nucleotide 
change 
Transcript 
AA 
change 
dbSNP rs/ss 
number 
Selection/exclusion 
criteria 
1 865,665 SAMD11 G/A NM_152486 R68Q rs145442390 
Does not segregate with 
disease 
1 1,961,467 GABRD G/A NM_000815 G369S rs199865640 
Does not segregate with 
disease 
1 226,573,339 PARP1 G/A NM_001618 L293F rs149619679 
Does not segregate with 
disease 
1 228,505,276 OBSCN G/T NM_001098623 R4558L rs199865640 
Does not segregate with 
disease 
1 230,921,738 CAPN9 G/A NM_016452 G472E ss1467426444 
Does not segregate with 
disease 
4 52,943,043 SPATA18 C/T NM_145263 P286L rs150116592 
MS frequency = 0.001 
Control frequency = 0 
4 148,886,277 ARHGAP10 C/A NM_024605 T518K rs375188932 Private variant 
4 155,254,540 DCHS2 G/C NM_001142552 H940Q rs79215995 Control frequency = 0.01 
5 40,852,774 CARD6 T/C NM_032587 L447P rs143022216 
Does not segregate with 
disease 
5 57,790,693 GAPT A/T NM_152687 E110D rs147191680 
Does not segregate with 
disease 
5 94,927,243 ARSK C/T NM_198150 P337L rs149766065 
Does not segregate with 
disease 
5 98,224,802 CHD1 T/A NM_001270 Y774F rs144567251 
Does not segregate with 
disease 
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5 123,980,164 ZNF608 T/C NM_020747 K1299R rs113873110 Control frequency = 0.03 
5 135,396,541 TGFBI G/C NM_000358 V608L ss1467426521 Private variant 
5 147,661,772 SPINK13 T/C NM_001040129 C72R ss1467426567 Private variant 
5 176,798,224 RGS14 G/A NM_006480 R438K ss1467426609 
Does not segregate with 
disease 
6 161,152,085 PLG G/A NM_000301 G420D rs139071351 
MS frequency = 0.005 
Control frequency = 0.001 
10 99,240,767 MMS19 C/T NM_022362 R65Q ss1467426865 
Does not segregate with 
disease 
15 42,185,151 SPTBN5 G/A NM_016642 R74C rs62002144 
Does not segregate with 
disease 
15 44,865,000 SPG11 T/C NM_001160227 N1962S rs140824939 
Does not segregate with 
disease 
16 66,804,108 CCDC79 G/T NM_001136505 S459R rs189708354 
Does not segregate with 
disease 
17 3,301,419 OR1E1 C/A NM_003553 D96Y ss1467426912 Private variant 
17 33,507,649 UNC45B G/A NM_001033576 R776Q rs34242925 
MS frequency = 0.0005 
Control frequency = 0.001 
20 68,396 DEFB125 C/T NM_153325 R16W rs138777928 Control frequency = 0.01 
22 46,780,446 CELSR1 C/T NM_014246 E2293K rs140996267 
Does not segregate with 
disease 
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Supplementary Table 3. Clinical features for PLG p.G420D carriers. RR, Relapsing-
remitting MS; PP, primary progressive MS; SP, secondary progressive MS; EDSS, expanded 
disability status scale; NA, not available. 
 
Pedigree Individual Gender Disease course Age 
Age at 
onset 
Disease 
duration 
EDSS 
score 
A II-1 F RR 69 41 28 - 
A II-3 M PP 65 26 39 - 
A II-4 M RR 63 44 19 2 
A II-7 F RR 58 20 38 - 
A II-9 F RR 52 23 29 - 
B II-2 F RR 59 35 24 3.5 
C III-1 F RR 52 37 15 3 
D III-1 F RR 55 36 19 2 
E III-2 F SP 53 26 27 8 
F II-6 M RR 66 54 12 6.5 
G III-1 F PP 53 45 8 - 
G III-3 M RR 41 27 14 1 
H II-4 F RR 50 44 6 1 
I II-4 F SP 43 31 12 7.5 
J II-1 F RR 59 37 22 8 
L II-1 F RR 43 40 3 2.5 
M II-1 M - 53 30 23 2 
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Supplementary Table 4. Logistic regression analysis for PLG-tagging SNPs. P-values were corrected for age and gender. Odds 
ratios (OR) and 95% confidence intervals (CI) are provided on the minor allele. 
 
dbSNP Genotypes Controls n (%) Multiple sclerosis n (%) p-value OR (95% CI) 
rs9458005 AA/AG/GG 476 (0.58) 297 (0.36) 51 (0.06) 1193 (0.60) 705 (0.35) 98 (0.05) 0.618 0.92 (0.78-1.09) 
rs2144723 CC/CT/TT 231 (0.28) 409 (0.50) 182 (0.22) 557 (0.28) 990 (0.50) 448 (0.22) 0.274 1.01 (0.84-1.21) 
rs1830519 AA/AG/GG 438 (0.53) 323 (0.39) 61 (0.07) 1120 (0.56) 742 (0.37) 135 (0.07) 0.154 0.89 (0.76-1.05) 
rs783147 GG/GA/AA 244 (0.30) 394 (0.48) 184 (0.22) 599 (0.30) 1031 (0.52) 366 (0.18) 0.307 0.98 (0.82-1.18) 
rs783146 CC/CG/GG 571 (0.69) 225 (0.27) 28 (0.03) 1420 (0.71) 528 (0.26) 46 (0.02) 0.265 0.91 (0.76-1.09) 
rs2295368 GG/GA/AA 301 (0.37) 402 (0.49) 121 (0.15) 656 (0.33) 1007 (0.50) 333 (0.17) 0.256 1.18 (0.99-1.39) 
rs4252135 GG/GT/TT 414 (0.50) 332 (0.40) 77 (0.09) 1008 (0.51) 820 (0.41) 163 (0.08) 0.719 0.99 (0.84-1.16) 
rs4252170 TT/TC/CC 683 (0.83) 129 (0.16) 13 (0.02) 1682 (0.84) 298 (0.15) 14 (0.01) 0.789 0.89 (0.72-1.11) 
rs783176 AA/AG/GG 556 (0.67) 228 (0.28) 41 (0.05) 1375 (0.69) 557 (0.28) 65 (0.03) 0.065 0.93 (0.79-1.11) 
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Supplementary Table 5. PLG-coding variants identified in MS patients. Allele frequencies 
from the NHLBI GO Exome Sequencing Project (ESP), the 1000 Genomes Project (1000G), and 
The Exome Aggregation Consortium (ExAC) are provided. Chromosomal positions are provided 
in reference to NCBI Build 37.1. NR, not reported. 
 
Chr Position 
Nucleotide 
change 
Protein 
change 
dbSNP rs/ss ID 
Minor allele frequency 
ESP 1000G ExAC 
6 161127501 A/G p.K38E rs73015965 0.004 0.003 0.003 
6 161128812 G/A p.R89K rs143079629 0.008 0.003 0.007 
6 161132146 C/T p.N110N rs4757 0.37 0.25 0.26 
6 161134069 G/A p.R153R rs144153702 0.001 NR 0.001 
6 161135876 A/G p.T200A rs149145958 0.001 0.001 0.001 
6 161137779 T/C p.C257C rs14224 0.45 0.45 0.42 
6 161137790 G/A p.R261H rs4252187 0.003 0.002 0.003 
6 161139480 C/T p.F314F rs1130656 0.36 0.37 0.38 
6 161139857 A/G p.Q361Q rs13231 0.26 0.16 0.22 
6 161152107 G/A p.R427R rs149909079 0.004 0.001 0.003 
6 161152155 C/T p.S443S ss1467426691 NR NR 0.00001 
6 161152206 T/A p.S460R rs116573785 0.01 0.02 0.006 
6 161152240 G/A p.D472N rs4252125 0.26 0.16 0.22 
6 161152257 C/T p.S477S rs4699 0.003 0.002 0.001 
6 161152807 G/A p.R490Q rs140537724 0.002 0.001 0.001 
6 161152819 C/T p.A494V rs4252128 0.009 0.01 0.008 
6 161152837 C/T p.T500M rs140970354 0.0004 0.001 0.0002 
6 161152858 C/T p.A507V rs372603134 0.0002 NR 0.0001 
6 161152905 C/T p.R523W rs4252129 0.01 0.003 0.007 
6 161159619 T/C p.L618L rs4252195 0.005 0.001 0.003 
6 161162406 T/C p.A694A rs4252170 0.06 0.08 0.07 
6 161173946 G/T p.G762G rs11060 NR 0.31 0.61 
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